silmitasertib
Small moleculeexperimental
Silmitasertib (INN), codenamed CX-4945, is a small-molecule inhibitor of protein kinase CK2, a constitutively active serine/threonine-specific protein kinase that is overexpressed in several types of tumors. — Wikipedia
Clinical trial activity
10 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00891280)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 1
- Breast Neoplasms · Phase 1
- Castleman Disease · Phase 1
- Cholangiocarcinoma · Phase 1/Phase 2
- Community-Acquired Infections · Phase 2
- Coronavirus · Phase 2
- COVID-19 · Phase 2
- Inflammatory Breast Neoplasms · Phase 1
- Liposarcoma · Phase 1/Phase 2
- Medulloblastoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1
- Neuroblastoma · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Pneumonia · Phase 2
- Rhabdomyosarcoma · Phase 1/Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
Mechanism of action
- Casein kinase II alphaINHIBITOR
CSNK2A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12- Mol. weight
- 349.78 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSilmitasertib ↗
- ChEMBLCHEMBL1230165 ↗
Also known as
- 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid
- cx4945
- cx 4945
- cx-4945
- cx-4945
- cx-4945
- cx-4945
- silmitasertib
- silmitasertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06541262 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2024 | Pennsylvania State University |
| NCT06202521 | Phase 2 | Feb 27, 2024 | Senhwa Biosciences, Inc. |
| NCT05817708 | Phase 1 | Nov 7, 2022 | Senhwa Biosciences, Inc. |
| NCT04668209 | Phase 2 | Dec 15, 2020 | Senhwa Biosciences, Inc., University of Arizona |
| NCT04663737 | Phase 2 | Dec 3, 2020 | Senhwa Biosciences, Inc. |
| NCT03904862 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2019 | National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, St. Jude Children's Hospital, University of Cincinnati |
| NCT03897036 | Phase 1 | Apr 1, 2019 | Senhwa Biosciences, Inc. |
| NCT02128282 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Mayo Clinic, Senhwa Biosciences, Inc. |
| NCT01199718 | Phase 1 | Sep 1, 2010 | Cylene Pharmaceuticals |
| NCT00891280 | Phase 1 | Feb 1, 2009 | Cylene Pharmaceuticals |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Senhwa Biosciences, Inc. | For profit | 6 | 5 | 2 | 2014 |
| Cylene Pharmaceuticals | For profit | 2 | 2 | 1 | 2009 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Pennsylvania State University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2019 |
9 organizations
Page 1 / 1